Introduction
Approximately 25% of adult patients with acute myeloid leukemia (AML) harbor internal tandem duplications (ITDs) within the juxtamembrane (JM) domain of the FLT3 gene. [1] [2] [3] [4] [5] FLT3/ITDs cause JM structural changes that disrupt the autoinhibitory conformation of the receptor, 6 promoting constitutive activation of the receptor and downstream effectors. [7] [8] [9] [10] [11] [12] [13] Although FLT3/ITDs are associated with a worse prognosis, [1] [2] [3] [4] [5] [14] [15] [16] [17] [18] subgroup analyses have further risk-stratified FLT3/ITD+ patients based upon mutant/wild-type allelic ratios and genetic expression patterns, suggesting that biological and clinical differences exist between the various FLT3/ITDs. 4, 18, 19 The sizes of FLT3/ITDs vary dramatically, 14 creating a large array of different insertions within the JM domain. Previous studies have not investigated the prognostic significance of ITD size in AML; [1] [2] [3] [4] [5] 15 -18 therefore, we examined whether the sizes of FLT3/ITDs were associated with a clinical outcomes.
Materials and Methods

Patients and Samples
Diagnostic bone marrow or peripheral blood samples from patients enrolled in patients). Centrally reviewed cytogenetic data, as previously described, were also included. 23 Associations between continuous variables were measured by
Spearman's rank order correlation coefficient (R). Comparisons between groups of
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From patients were based on Wilcoxon's rank sum test for continuous variables, and on logistic and proportional hazards regression analyses for dichotomous and time-toevent data, respectively. Outcomes analyzed included complete response (CR) and resistant disease (RD). Overall survival (OS) was measured from date of study entry until death from any cause. For patients who achieved a CR, relapse-free survival (RFS) was measured from the date that CR was achieved until relapse or death from any cause, with observation censored at the date of last contact for patients known alive without report of relapse. In analyses of treatment outcomes, ITD size was treated as a continuous variable with value 0 for FLT3/ITD-patients. Since studies S9500 and S9333 investigated somewhat different chemotherapy regimens in patients with different age ranges, all analyses of treatment outcomes were adjusted for differences between studies. Statistical significance was represented by twosided p-values.
Results and Discussion
Cryopreserved diagnostic samples were available from 160 (63%) of the 256 AML patients enrolled on study S9500 or the AD arm of S9333. The included patients had significantly (p<0.001) higher WBC (median 31.9 vs. 4.1), peripheral blast percentage (46% vs. 8%), and marrow blast percentage (73% vs. 58%) than the 96 patients without available material. The two groups did not differ significantly with respect to CR rate (p=0.55), RD rate (p=0.51), or OS (p=0.44), although the included patients had somewhat better RFS (p=0.088).
Diagnostic samples of 151 patients (94%) were successfully screened for FLT3/ITDs using PCR/SSCP analyses.
14 FLT3/ITDs were found in 48 patients (32%, for patients with large, small, and no ITDs, respectively. Likewise, RFS tended to decrease with increasing ITD size (p=0.017), with estimated probabilities of 5-year RFS equal to 13%, 27%, and 34%, respectively. The effect of ITD size on OS was somewhat stronger in patients from study S9333 (age 56-84), with the mortality For personal use only. on August 31, 2017. by guest www.bloodjournal.org From hazard increasing an estimated 1.3% for each additional nucleotide, compared to 0.3% for S9500 (age 18-55); however, the difference in trends between the two studies was not statistically significant (p=0.17, Figure 2 
95% confidence interval [CI] 24-40%). ITDs were associated with higher WBC
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From (median 40.5 vs. 28.4, p=0.0080), higher marrow blast percentage (median 79% vs.personal use only. on August 31, 2017. by guest www.bloodjournal.org From Figure Legends
